Denny Ardhianto (2020) Analisis Efek Samping Pemanjangan QT Interval Pada Regimen Bedaquilin Pada Pasien TB-RO (Penelitian dilaksanakan di Poli TB-MDR RSUD Dr. Soetomo Surabaya). Thesis thesis, UNIVERSITAS AIRLANGGA.

	Text (HALAMAN JUDUL) 1. HALAMAN JUDUL.pdf Download (299kB)
	Text (ABSTRACT) 2. ABSTRACT.pdf Download (167kB)
	Text (DAFTAR ISI) 3. DAFTAR ISI.pdf Download (253kB)
	Text (BAB 1) 4. BAB 1 PENDAHULUAN.pdf Download (188kB)
	Text (BAB 2) 5. BAB 2 TINJAUAN PUSTAKA.pdf Restricted to Registered users only until 15 December 2023. Download (619kB) | Request a copy
	Text (BAB 3) 6. BAB 3 KERANGKA KONSEPTUAL.pdf Restricted to Registered users only until 15 December 2023. Download (227kB) | Request a copy
	Text (BAB 4) 7. BAB 4 METODE PENELITIAN.pdf Restricted to Registered users only until 15 December 2023. Download (200kB) | Request a copy
	Text (BAB 5) 8. BAB 5 HASIL PENELITIAN.pdf Restricted to Registered users only until 15 December 2023. Download (457kB) | Request a copy
	Text (BAB 6) 9. BAB 6 PEMBAHASAN.pdf Restricted to Registered users only until 15 December 2023. Download (222kB) | Request a copy
	Text (BAB 7) 10. BAB 7 KESIMPULAN DAN SARAN.pdf Restricted to Registered users only until 15 December 2023. Download (164kB) | Request a copy
	Text (DAFTAR PUSTAKA) 11. DAFTAR PUSTAKA.pdf Download (213kB)
	Text (LAMPIRAN) 12. LAMPIRAN.pdf Restricted to Registered users only until 15 December 2023. Download (1MB) | Request a copy
	Text (EMBARGO) 13. Embargo Denny Ardhianto.pdf Restricted to Registered users only Download (696kB) | Request a copy

Abstract

BACKGROUND - Indonesia is one of the top 20 countries with the highest prevalence of DR-TB worldwide with a percentage of new cases of 2.4% and re-treatment of 13%. Bedaquiline (BDQ) is one of the drugs that used in the individual long regimen treating DR-TB. Bedaquiline is also combined with levofloxacine (LFX) and/or clofazimine (CFZ) that can cause QT interval prolongation. OBJECTIVE - The aim was to study the differences in the use of BDQ regimens to the lengthening of the QT interval and to study risk factors (diabetes, hypokalemia, sex, BMI and age) in BDQ regimen. METHOD - This study was an observational retrospective study with a total sampling method, which was conducted at Dr. Soetomo Hospital Surabaya. Samples from this study were patients diagnosed with DR-TB at RSUD Dr. Soetomo Surabaya in the period of January 2015 - December 2019 who used BDQ regimen and met the inclusion criteria. RESULTS - Data obtained from total sample in this study were 73 patients. The most widely used different regimens in this study were the combination of BDQ+LFX by 36 patients (49.3%), BDQ+LFX+CFZ by 16 patients (21.9%), BDQ by 11 patients (15.1%) and BDQ+CFZ 10 patients (13.7%). Out of 73 patients, 52 patients (71,2%) experienced lengthening of the QT interval and grade 1 of QTc interval prolongation occurred in most patients and also the onset was mostly one month after using BDQ regimen. The side effects of QT interval prolongation from groups of combination and risk factors were no difference in each month (p> 0.05). CONCLUSION - This study can be concluded that there are no differences in the QT prolongation between the groups of bedaquiline regimen (BDQ, BDQ+LFX, BDQ+CFZ and BDQ+LFX+CFZ) and the groups of risk factors.

Actions (login required)

View Item